

Disclosure of Interests: Mikkel Østergaard Speakers bureau: AbbVie, BMS, Boehringer-Ingelheim, Eli Lilly, Janssen, Merck, Pfizer, Roche, UCB, Celgene, Sanofi, Regeneron, Novartis, Orion, Hospira, Consultant of: AbbVie, BMS, Boehringer-Ingelheim, Eli Lilly, Janssen, Merck, Pfizer, Roche, UCB, Celgene, Sanofi, Regeneron, Novartis, Orion, Hospira, Grant/research support from: AbbVie, BMS, Merck, UCB, Celgene, Novartis, Ronald van Vollenhoven Speakers bureau: AbbVie, AstraZeneca, Biogen, Celgene, Galapagos, Gilead, Janssen, Pfizer, Servier, UCB, Consultant of: AbbVie, AstraZeneca, Biogen, Celgene, Galapagos, Gilead, Janssen, Pfizer, Servier, UCB, Grant/research support from: BMS, GSK, Eli Lilly, UCB, Pfizer, Roche, Anna Rudin Grant/research support from: AstraZeneca, Merete L. Hetland Speakers bureau: Merck, Biogen, Pfizer, Eli Lilly, Orion Pharma, CellTrion, Samsun Bioepsi, Janssen Biologics BV, MSD, Consultant of: Merck, Biogen, Pfizer, Eli Lilly, Orion Pharma, CellTrion, Samsun Bioepsi, Janssen Biologics BV, MSD, Grant/research support from: BMS, AbbVie, Roche, Novartis, Merck, Biogen, Pfizer, Marte Heiberg Speakers bureau: Eli Lilly, Consultant of: Eli Lilly, Dan Nordström Grant/research support from: UCB, BMS, AbbVie, Celgene, MSD, Novartis, Pfizer, Michael Nurmohamed Speakers bureau: Celltrion, Eli Lilly, Consultant of: Celltrion, Eli Lilly, Grant/research support from: BMS, AbbVie, MSD, Pfizer, Amgen, Björn Gudbjornsson Speakers bureau: Novartis, Consultant of: Novartis, Lykke Midtbøll Ørnberg Grant/research support from: Novartis, Pernille Bøyesen: None declared, Inge Olsen: None declared, Kristina Lend: None declared, Kim Hørslev-Petersen: None declared, Till Uhlig Speakers bureau: Grünenthal, Eli Lilly, Novartis, Pfizer, Consultant of: Grünenthal, Eli Lilly, Novartis, Pfizer, Grant/research support from: NORDFORSK, Tuulikki Sokka-Isler Speakers bureau: AbbVie, BMS, Celgene, Medac, Merck, Novartis Orion Pharma, Pfizer, Roche, Sandoz, UCB, Boehringer Ingelheim, Consultant of: AbbVie, BMS, Celgene, Medac, Merck, Novartis Orion Pharma, Pfizer, Roche, Sandoz, UCB, Boehringer Ingelheim, Gerdur Gröndal: None declared, Simon Krabbe Grant/research support from: AbbVie, MSD, Novartis, Joakim Lindqvist: None declared, Inger Gjertsson: None declared, Daniel Glinatsi Speakers bureau: AbbVie, Eli Lilly, Consultant of: AbbVie, Eli Lilly, Meliha C Kapetanovic: None declared, Anna-Birgitte Aga Speakers bureau: AbbVie, Eli Lilly, Novartis, Pfizer, Consultant of: AbbVie, Eli Lilly, Novartis, Pfizer, Francesca Faustini: None declared, Pinja Parmanne Speakers bureau: Novartis, Consultant of: Novartis, Tove Lorenzen Speakers bureau: UCB, Consultant of: UCB, Giovanni Cagnotto: None declared, Johan Back: None declared, Oliver Hendricks Speakers bureau: AbbVie, Novartis, Consultant of: AbbVie, Novartis, Daisy Vedder: None declared, Tuomas Rannio: None declared, Emma Grenholm: None declared, Hanne Merete Lindegaard: None declared, Maud-Kristine A Ljosa: None declared, Eli Brodin: None declared, Annika Soderbergh: None declared, Milad Rizk: None declared, Elsa Hermansson: None declared, Line Uhrenholt Speakers bureau: AbbVie, Eli Lilly, Novartis, Consultant of: AbbVie, Eli Lilly, Novartis, Per Larsson: None declared, Søren Andreas Just: None declared, Gunnstein Bakland Speakers bureau: BMS, Consultant of: BMS, David Stevens Grant/research support from: KLINBEFORSK, Trine Bay Laurberg Speakers bureau: UCB, Consultant of: UCB, Espen A Haavardsholm Speakers bureau: Pfizer, AbbVie, Celgene, Novartis, Janssen, Gilead, Eli Lilly, UCB, Consultant of: Pfizer, AbbVie, Celgene, Novartis, Janssen, Gilead, Eli Lilly, UCB, Grant/research support from: NORDFORSK, Jon Lampa: None declared.

DOI: 10.1136/annrheumdis-2022-eular.868

OP0059 **PROFOUND ANTICOAGULANT EFFECTS OF INITIAL ANTIRHEUMATIC TREATMENTS IN EARLY RHEUMATOID ARTHRITIS PATIENTS: A NORD-STAR SPIN-OFF STUDY**

B. Dijkshoorn¹, A. Antovic², D. Vedder¹, A. Rudin³, D. Nordström⁴, B. Gudbjornsson^{5,6}, K. Lend^{7,8}, T. Uhlig^{9,10}, E. A. Haavardsholm⁹, G. Gröndal⁵, M. L. Hetland^{11,12}, M. Heiberg⁹, M. Østergaard^{11,12}, K. Hørslev-Petersen^{13,14}, J. Lampa⁵, R. Van Vollenhoven^{7,8}, M. Nurmohamed^{1,7}. ¹Amsterdam Rheumatology & immunology center location Reade, Rheumatology, Amsterdam, Netherlands; ²Karolinska Institute, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden; ³Sahlgrenska Academy, Gothenburg University, Department of Rheumatology and Inflammation research, Göteborg, Sweden; ⁴Helsinki University Hospital, Department of Rheumatology, Helsinki, Finland; ⁵Landspítali University Hospital, Centre for Rheumatology Research, Reykjavik, Iceland; ⁶University of Iceland, Faculty of Medicine, Reykjavik, Iceland; ⁷Amsterdam University Medical Centers, Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam, Netherlands; ⁸Karolinska Institute, Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Stockholm, Sweden; ⁹Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway; ¹⁰University of Oslo, Faculty of Medicine, Oslo, Norway; ¹¹Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Glostrup, Denmark; ¹²University

of Copenhagen, Department of Clinical Medicine, Faculty of Health Sciences, Copenhagen, Denmark; ¹³University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark; ¹⁴University of Southern Denmark, Department of Regional Health Research, Odense, Denmark

Background: Patients with rheumatoid arthritis (RA) are at an increased risk of venous thromboembolism. Thus far, there have not been any comparative studies investigating the effects of initial antirheumatic treatments in (very) early RA patients.

Objectives: To assess the effects of different initial treatments on hemostatic parameters in patients with early RA.

Methods: NORD-STAR is an international, multicentre, open-label, assessor-blinded, phase 4 study where patients with newly diagnosed RA started methotrexate (MTX) and were randomised 1:1:1 to a) conventional treatment (either prednisolone tapered to 5mg/day, or sulfasalazine combined with hydroxychloroquine and intra-articular corticosteroids), b) certolizumab pegol, c) abatacept, d) tocilizumab¹. This study is a spin-off from the main NORD-STAR study extensively investigating hemostatic system in 24 per protocol consecutive Dutch participants at baseline, 12 weeks and 24 weeks after the start of the treatment. Statistical analysis was done using paired samples t-test in SPSS version 28.

Results: The mean age of investigated patients was 51.8 (± 12.7) years and 58.3% were female. At baseline patients had an average DAS28 score of 4.6 (± 0.9) and had elevated levels of investigated coagulation biomarkers: Factor 1 + 2, fibrinogen, D-dimer and parameters of the two global hemostatic assays, i.e. endogenous thrombin potential (ETP) and overall hemostasis potential (OHP). These biomarkers decreased significantly at 12 and 24 weeks in patients in all groups (Table 1). Overall fibrinolytic potential (OFP) was decreased and clot lysis time (CLT) was prolonged at baseline, demonstrating impaired fibrinolytic activity in early RA. The reduction of coagulation parameters was significantly higher in biological treatment arms in comparison to the standard MTX treatment arm. In addition, tocilizumab was more effective compared to certolizumab and abatacept, (Figure 1), which was expected considering the direct inhibitory effect of this drug on the IL-6 synthesis and consequently the coagulation activation as well. After 24 weeks of treatment with methotrexate and tocilizumab, the average fibrinogen of patients was reduced by 63% vs 31% and 36% in the certolizumab and abatacept groups, respectively. The changes in DAS-28 and the changes in fibrinogen had a correlation of 0.385 which did not reach statistical significance.

Table 1. Measurements are marked with * if p<0.05, ** if p<0.01 and * if p<0.001**

	Baseline	W12	W24
Factor 1 + 2 (pmol/L)	270.25 (149.4)	190.36 (108.6)**	179.52 (85.3)***
Fibrinogen (g/L)	4.64 (1.5)	3.61 (1.6)**	2.63 (1.2)***
D-dimer (mg/L)	2.17 (3.0)	0.33 (0.23)**	0.29 (0.2)**
OHP (Abs-sum)	157.38 (64.9)	120.62 (68.7)*	100.49 (53.8)***
OCP (Abs-sum)	369.52 (58.8)	305.04 (101.7)*	275.91 (83.1)***
OFP (%)	57.97 (13.1)	63.20 (12.7)*	65.25 (11.4)***
Lag time (s)	304.5 (71.1)	306.8 (71.8)	312.7 (65.4)
Slope	0.07 (0.02)	0.066 (0.03)	0.094 (0.12)
Max Abs	1.17 (0.3)	1.00 (0.4)*	0.91 (0.3)**
CLT (s)	1405 (356)	1317 (377)	1231 (320)**
ETP (nM*min)	1480 (471)	1395 (395)*	1337 (429)*
Peak (nM)	231 (78)	223 (68)	223 (74)
Lagtime (min)	4.06 (2.1)	3.28 (1.2)**	2.87 (1.0)***
ttPeak (min)	7.40 (2.2)	6.61 (1.5)*	6.13 (1.4)**




Figure 1.

Conclusion: Our results indicate an enhanced coagulation and fibrinolytic impairment in newly diagnosed RA patients. Effective antirheumatic treatments reduce this hemostatic imbalance, with significantly more pronounced effects of biologic drugs compared to conventional (MTX+glucocorticoids) treatment.

REFERENCES:

[1] Hetland M et al. *BMJ*. 2020

Disclosure of Interests: Bas Dijkshoorn: None declared, Aleksandra Antovic: None declared, Daisy Vedder: None declared, Anna Rudin: None declared, Dan Nordström Speakers bureau: Novartis, UCB, Consultant of: Abbvie, BMS, Lilly, Novartis, Pfizer, Roche, UCB, Björn Gudbjornsson Speakers bureau: Amgen and Novartis - not related to this work, Consultant of: Novartis - not related to this work, Kristina Lend: None declared, Till Uhlig Speakers bureau: Grünenthal, Novartis, Consultant of: Grünenthal, Novartis, Grant/research support from: NORDFORSK, Espen A Haavardsholm Consultant of: Pfizer, AbbVie, Celgene, Novartis, Janssen, Gilead, Eli-Lilly, UCB, Grant/research support from: NORDFORSK, Norwegian Regional Health Authorities, South-Eastern Norway Regional Health Authority, Gerður Gröndal: None declared, Merete Lund Hetland Consultant of: Abbvie, Biogen, BMS, Celltrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Fonden, MSD, Pfizer, Roche, Samsung Biopics, Sandoz, Novartis, Grant/research support from: Abbvie, Biogen, BMS, Celltrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Fonden, MSD, Pfizer, Roche, Samsung Biopics, Sandoz, Novartis, Marte Heiberg: None declared, Mikkel Østergaard Speakers bureau: Abbvie, BMS, Celgene, Eli-Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Orion, Pfizer, Roche and UCB, Consultant of: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Grant/research support from: Abbvie, Amgen, BMS, Merck, Celgene and Novartis, Kim Horslev-Petersen: None declared, Jon Lampa Speakers bureau: Pfizer, Janssen, Novartis, Ronald van Vollenhoven Speakers bureau: Abbvie, Galapagos, GSK, Janssen, Pfizer, R-Pharma, UCB, Consultant of: Abbvie, AstraZeneca, Biogen, BMS, Galapagos, Janssen, Miltenyi, Pfizer, UCB, Grant/research support from: BMS, GSK, UCB, Michael Nurmohamed Speakers bureau: Abbvie, Janssen, Celgene, Consultant of: Abbvie, Grant/research support from: Abbvie, Amgen, Pfizer, Galapagos, BMS.

DOI: 10.1136/annrheumdis-2022-eular.2288

OP0060

EXPOSURE TO SPECIFIC TUMOR NECROSIS FACTOR INHIBITORS AND RISK OF DEMYELINATING AND INFLAMMATORY NEUROPATHY IN PATIENTS WITH INFLAMMATORY ARTHRITIS. A COLLABORATIVE OBSERVATIONAL STUDY ACROSS FIVE NORDIC RHEUMATOLOGY REGISTERS

B. Delcoigne¹, T. I. Kopp², E. Arkema¹, K. Hellgren¹, S. Aarrestad Provan³, H. Relas⁴, K. Aaltonen⁵, N. Trokovic⁴, B. Gudbjornsson⁶, G. Gröndal⁶, E. Kristianslund³, L. Dreyer^{7,8}, J. Asklings¹. ¹Karolinska Institute, Clinical Epidemiology, Stockholm, Sweden; ²Copenhagen University Hospital - Rigshospitalet, The Danish Multiple Sclerosis Registry, Department of Neurology, Glostrup, Denmark; ³Diakonhjemmet Hospita, Division of Rheumatology and Research, Oslo, Norway; ⁴Helsinki University Hospital and Helsinki University, ROB-FIN, Department of Medicine and Rheumatology, Helsinki, Finland; ⁵Ministry of Social Affairs and Health, ROB-FIN, Pharmaceuticals Pricing Board, Helsinki, Finland; ⁶University of Iceland, Centre for Rheumatology Research, Landspítali University Hospital, and Faculty of Medicine, Reykjavik, Iceland; ⁷Aalborg University, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark; ⁸DANBIO Registry, DANBIO Registry, Copenhagen, Denmark

Background: Though rare, studies have reported increased risk of neurological events including demyelinating disease of CNS (DML), multiple sclerosis (MS), and inflammatory neuropathy (INP) in patients with inflammatory joint disease treated with tumor necrosis factor inhibitors (TNFi).^{1,2} More in-depth investigations are required to elucidate the association between TNFi and neurological events in these patients, especially whether rates differ across type of TNFi mode of action.

Objectives: To estimate the incidence of neurological events in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA, including axial spondyloarthritis and psoriatic arthritis) starting treatment with TNFi across five Nordic countries. To compare the incidence of neurological events in etanercept (ETN)-treated patients to patients treated with other TNFi (oTNFi).

Methods: We defined treatment cohorts of patients initiating TNFi between 2001 through 2018 from clinical rheumatology registers in Denmark (DK), Finland (FI),

Iceland (IS), Norway (NO), and Sweden (SE). One patient could contribute to more than one treatment episode. Demographic data (sex, age), co-medication (methotrexate) and clinical variables (CRP, disease duration (<1 year, 1 to 5 years, >5 years)) were extracted and used as covariates. We estimated crude incidence rates (IR) for neurological events and subtypes (ICD-10 codes: MS: G35, DML: G35, G36.0, G36.8-9, G37.1, G37.3, G37.5, G37.8-9, H46, H48.1, G04.8-9, INP: G61.0, G61.8-9), all countries pooled. We compared risk of neurological events between patients treated with ETN and oTNFi using Cox regression with time since treatment start, adjusted for the above covariates, robust standard errors, and stratified by country.

Results: We included 52,682 treatment starts, in 33,885 RA patients (DK 8,259, FI 3,765, IS 723, NO 1353, SE 19,785; 75% women, mean age 56 years) and 46,549 treatment starts in 28,772 SpA patients (DK 7,000, FI 2,885, IS 962, NO 2,684, SE 15,241; 47% women, mean age 45 years).

Numbers of DML, MS, INP and all neurological events, person-years (pyrs), and IRs in RA and SpA patients, for the two treatment groups are displayed in Figure 1. IRs for these neurological events showed some variation by diagnosis (RA vs. SpA), with rates of DML (and MS) in SpA patients around two (and three, respectively) times higher than the corresponding rates in RA ($p < 0.01$), but similar rates for INP in RA and SpA patients. Comparing oTNFi to ETN, all Cox regression hazard ratios (HR) were statistically non-significant and close to one, whatever the outcome and the group of patients (Figure 1), with the adjusted HR (95%CI) for developing any neurological event in oTNFi compared to ETN being 1.08 (0.91-1.28) in RA patients and 0.96 (0.78-1.19) in SpA patients.




Figure 1. Number of events, pyrs and IRs of DML, MS, INP and all neurological events (NE) in RA and SpA patients, treated with ETN or oTNFi. HRs (95%CI) comparing oTNFi to ETN.

Conclusion: The incidences of DML and MS were lower in RA compared to SpA patients, while rates of INP were similar in both patients' groups. There was no evidence of differences in these rates between ETN and oTNFi. The findings are of importance from a safety perspective for patients starting TNFi.

REFERENCES:

[1] Kopp T *ARD* 2020;79(5):566

[2] Kunchok A *JAMA Neurol* 2020;77(8):937

Acknowledgements: NordForsk and Forum partially funded this research project.

Disclosure of Interests: Bénédicte Delcoigne: None declared, Tine Iskov Kopp Paid instructor for: T. I. Kopp has served on scientific advisory board from Novartis, Consultant of: T. I. Kopp has received support to congress participation from Biogen, Grant/research support from: T. I. Kopp has received support to congress participation from Biogen, Elizabeth Arkema: None declared, Karin Hellgren: None declared, Sella Aarrestad Provan: None declared, Heikki Relas Paid instructor for: Abbvie, Pfizer, Kalle Aaltonen: None declared, Nina Trokovic: None declared, Björn Gudbjornsson Speakers bureau: Novartis - not related to this work, Consultant of: Novartis - not related to this work, Gerður Gröndal: None declared, Eirik kristianslund: None declared, Lene Dreyer Speakers bureau: Speakers bureau: Eli Lilly, Galderma and Janssen, Grant/research support from: Grant from BMS outside the present work, Johan Asklings Grant/research support from: AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, Merck, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB.

DOI: 10.1136/annrheumdis-2022-eular.2866